YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SpyGlass Pharma, Inc. SpyGlass Pharma acquires 100% of the outstanding shares of AVS, a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), the existing manufacturer of SpyGlass Pharma's intraocular lens (IOL) Secures scalable commerci…
Ligand Pharmaceuticals Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royal…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent performance snapshot Santen Pharmaceutical (TSE:4536) has be…
TURKU, FI / ACCESS Newswire / March 26, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company's Chief Technical Offic…
* Santen Pharmaceutical Co., Ltd. press release [https://ssl4.eir-parts.net/doc/4536/tdnet/2750838/00.pdf] (SNPHY [https://seekingalpha.com/symbol/SNPHY]): 9M GAAP EPS of ¥66.05. * Revenue of ¥210.76B. MORE ON SANTEN PHARMACEUTICAL CO., LT…
BRIDGEWATER, N.J., Jan. 8, 2026 /PRNewswire/ -- RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketi…
(RTTNews) - Santen Pharmaceutical Co., Ltd. (SNPHY, 4536.T) announced the launch of Verkazia (Ciclosporin Eye Drops III) in China for the treatment of severe vernal keratoconjunctivitis (VKC) in children and young adults. With this introdu…
Koya Medical CEO Andy Doraiswamy Among the Most Exceptional Entrepreneurs at 2025 Builders and Innovators Summit DALLAS, Oct. 15, 2025 /PRNewswire/ -- Today, Goldman Sachs (NYSE: GS) is recognizing Koya Medical ("Koya") CEO Andy Doraiswamy…
Company Logo The global Fuchs Endothelial Corneal Dystrophy (FECD) market is experiencing robust growth, driven by advancements in corneal transplantation techniques, increased awareness of rare ocular diseases, and improved diagnostic cap…
Thinking about what to do with your Santen Pharmaceutical shares or whether now is the right time to jump in? You are not alone. The company’s journey over the past few years has definitely given investors plenty to talk about. Despite som…
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (Chin…
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (Chin…
Company Logo The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndr…
Company Logo Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor typ…
Santen Pharmaceutical just reported results for the fourth quarter of 2023.
Harrow Health Inc. is expanding its eye care offerings. The Nashville-based pharmaceutical company is purchasing the commercial rights to eight ophthalmic drugs in two separate transactions. Harrow (Nasdaq: HROW) will pay an initial paymen…
In this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompas…
By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT We are initiating coverage of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share. RVL’s lead and only marketed asset is Upneeq®, a product dev…
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. (GKOS) has entered into a license agreement with Santen Pharmaceutical Co. (SNPHF). Glaukos concentrates on therapies for the treatment of glaucoma, corneal disorders,…
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. (GKOS) has entered into a license agreement with Santen Pharmaceutical Co. (SNPHF). Glaukos concentrates on therapies for the treatment of glaucoma, corneal disorders,…